Alexander Burik, Author at Labiotech.eu

About

Born in Chicago, I grew up close to Frankfurt, Germany. I hold an MSc in Neuroscience from University College London and a BA in Biochemistry from Knox College in the US.
Outside of science-related activities, I enjoy skiing and writing music.

Articles by Alexander Burik

News and Trends 9 May 2018

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Memo Therapeutics has raised CHF 5M (€4,2M) to develop its antibody detection technology, which uses whole antibodies to reach difficult targets. Memo Therapeutics, a spin-off from ETH Zurich, has closed a Series A2 round of CHF 5M (€4,2M). The funding was provided by Redalpine Venture Partners and Zurich Cantonal Bank among other investors and will […]

May 9, 2018 - 1 minutemin - By Alexander Burik

News and Trends 4 May 2018

Bionic Implant to Restore Vision Raises Funding to Complete First Human Trial

Pixium Vision has raised €10.6M by offering new shares on Euronext Paris. The funding will be used to develop its bionic vision device further and bring it closer to a European market authorization. Pixium Vision, based in Paris, has raised €10.6M on Euronext Paris to continue the first clinical study of its PRIMA bionic vision system in […]

May 4, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 3 May 2018

FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease

Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form the FDA for its gene therapy OTL-200. The treatment is for patients with metachromatic leukodystrophy (MLD), a fatal genetic disease that causes […]

May 3, 2018 - 1 minutemin - By Alexander Burik

News and Trends 3 May 2018

World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s

uniQure has raised a substantial public offering on the NASDAQ. The funding could help the Dutch biotech advance two new gene therapies after the withdrawal of its first treatment. Amsterdam-based uniQure has raised an ambitious $128M (€107M) in a public offering at the beginning of next week. The Dutch biotech develops gene therapies for hemophilia and Huntington’s disease, for […]

May 3, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 30 Apr 2018

Record Series B Financing Supports Antibody Cancer Therapy

Crescendo Biologics has raised €57M in in the largest disclosed Series B financing in the European biotech sector this year. The company will use the funds to develop its antibody cancer treatment that activates white blood cells to fight tumors. Crescendo Biologics, based in Cambridge, UK, has raised €57M in the largest disclosed Series B financing for the European […]

April 30, 2018 - 2 minutesmins - By Alexander Burik

Startup Scout 27 Apr 2018

This Portuguese Biotech is Developing a Faster Antimicrobial Susceptibility Test

Today, we’re in Matosinhos, Portugal, visiting FASTinov, a biotech that is developing an antimicrobial susceptibility test that are faster than standard assays. The technology could help battle antibiotic resistance by identifying appropriate treatments. Mission: Founded in 2013, FASTinov is developing a new type of test for antimicrobial susceptibility that can help combat the global health problem of antibiotic […]

April 27, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 26 Apr 2018

Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US

Pluristem Therapeutics will start a Phase III trial this year in the US for its pioneering cell therapy that uses placenta cells to restore muscle injuries. Pluristem Therapeutics, an Israeli biotech and world-leader in cell therapies, has received a green light from the FDA to start a Phase III study in the US. The trial will test […]

April 26, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Apr 2018

Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time

Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, the first treatment of its kind, for advanced solid tumors. The news follows the Phase […]

April 25, 2018 - 1 minutemin - By Alexander Burik

News and Trends 24 Apr 2018

Fundraising Boosts Italian Red Blood Cell Therapy

EryDel has raised €26.5M to develop a red blood cell drug delivery system to treat a rare disease of the immune and nervous systems. Italian biotech EryDel has raised €26.5M to complete a Phase III trial testing a unique technology to treat ataxia telangiectasia, a rare genetic disorder. The fundraising was led by Sofinnova Partners, a leading European venture […]

April 24, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 24 Apr 2018

New Class of Antibiotics Combats the Three Deadliest Bacteria in the World

A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no […]

April 24, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 20 Apr 2018

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. The company plans to file for an EU approval of its treatment later this year. US firm bluebird bio has results from two clinical studies showing its LentiGlobin gene […]

April 20, 2018 - 2 minutesmins - By Alexander Burik

BenevolentAI Artificial Intelligence Fundraising

News and Trends 19 Apr 2018

Major $115M Fundraising Fuels AI Drug Development

BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities of its artificial intelligence technology. The technology could significantly increase the speed and efficiency of the drug discovery process. BenevelontAI, based in London, has raised an impressive $115M (€93M) to advance its use of AI in drug development. The funding, raised from […]

April 19, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us